This study is investigating emapalumab, a drug that targets a specific pathway (RAF) involved in the immune system, to see if it can prevent graft rejection in people who have received a hematopoietic stem cell transplant (HSCT). Graft rejection happens when the body's immune system attacks the new stem cells. Researchers believe that a substance called interferon gamma plays a key role in this process, and emapalumab works by blocking it. Participants will be high-risk for graft rejection, meaning they have certain factors like a mismatched donor or a history of rejection. They will receive either a 3 mg/kg or 10 mg/kg dose of emapalumab once, with the possibility of up to two additional doses if there are concerns about rejection. The main goal is to see how well emapalumab works to prevent rejection after 100 days. The study aims to enroll 20 participants.

Study design

This is an interventional study where participants will be randomly assigned to receive one of two different doses of emapalumab. It plans to enroll 20 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The preliminary efficacy of emapalumab will be measured at 100 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.